Cargando…

The International IgA Nephropathy Network Prediction Tool Underestimates Disease Progression in Indian Patients

INTRODUCTION: International IgA nephropathy (IgAN) network (IIgANN) prediction tool was developed to predict risk of progression in IgAN. We attempted to externally validate this tool in an Indian cohort because the original study did not include Indian patients. METHODS: Adult patients with primary...

Descripción completa

Detalles Bibliográficos
Autores principales: Bagchi, Soumita, Upadhyay, Ashish Datt, Barwad, Adarsh, Singh, Geetika, Subbiah, Arunkumar, Yadav, Raj Kanwar, Mahajan, Sandeep, Bhowmik, Dipankar, Agarwal, Sanjay Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171624/
https://www.ncbi.nlm.nih.gov/pubmed/35685319
http://dx.doi.org/10.1016/j.ekir.2022.03.016
Descripción
Sumario:INTRODUCTION: International IgA nephropathy (IgAN) network (IIgANN) prediction tool was developed to predict risk of progression in IgAN. We attempted to externally validate this tool in an Indian cohort because the original study did not include Indian patients. METHODS: Adult patients with primary IgAN were stratified to low, intermediate, higher, and highest risk groups, as per the original model. Primary outcome was reduction in estimated glomerular filtration rate (eGFR) by >50% or kidney failure. Both models were evaluated using discrimination: concordance statistics (C-statistics), time-dependent receiver operating characteristic (ROC) curves, R(2)d, Kaplan–Meier survival curves between risk groups and calibration plots. Reclassification with net reclassification improvement and integrated discrimination improvement (IDI) was used to compare the 2 models with and without race. RESULTS: A total of 316 patients with median follow-up of 2.8 years had 87 primary outcome events. Both models with and without race showed reasonable discrimination (C-statistics 0.845 for both models, R(2)d 49.9% and 44.7%, respectively, and well-separated survival curves) but underestimated risk of progression across all risk groups. The calibration slopes were 1.234 (95% CI: 0.973–1.494) and 1.211 (95% CI: 0.954–1.468), respectively. Both models demonstrated poor calibration for predicting risk at 2.8 and 5 years. There was limited improvement in risk reclassification risk at 5 and 2.8 years when comparing model with and without race. CONCLUSION: IIgANN prediction tool showed reasonable discrimination of risk in Indian patients but underestimated the trajectory of disease progression across all risk groups.